HCPCS G9844: Patient Did Not Receive Anti-EGFR Monoclonal Antibody Therapy - OpenPayer

Summary & Overview

HCPCS G9844: Patient Did Not Receive Anti-EGFR Monoclonal Antibody Therapy

HCPCS Level II code G9844 documents that a patient did not receive anti-EGFR monoclonal antibody therapy. Nationally, clear documentation of therapy non-receipt is important for accurate claims processing, quality measurement, and clinical records in oncology care. This code provides a standardized way to indicate omission of a specific targeted biologic therapy.

Key payers included in this context are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, typical clinical settings where it is used, and the implications for claims and recordkeeping. The analysis covers benchmarking approaches and payer coverage considerations, policy relevance for oncology treatment documentation, and the clinical context around anti-EGFR monoclonal antibody therapy.

The publication outlines practical billing and documentation elements associated with G9844, summarizes common modifiers seen on related service lines, and indicates where input data were not provided. The goal is to offer a clear national perspective on the code's role in oncology billing and administrative workflows.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9844HCPCS Level IIoncologyanti-EGFRbiologic therapyinfusion clinicclaims documentationtreatment omission

Billing Code Overview

HCPCS Level II code G9844 indicates that the patient did not receive anti-EGFR monoclonal antibody therapy. The service type is documentation of non-receipt of a specified biologic therapy. The typical site of service is the outpatient oncology infusion clinic or other ambulatory cancer care setting where decisions about systemic anticancer therapy are documented.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A patient with metastatic colorectal cancer or another solid tumor that is routinely tested for epidermal growth factor receptor (EGFR) expression or RAS mutation status is evaluated for monoclonal anti-EGFR therapy (for example, cetuximab or panitumumab). During oncology clinic or infusion center workflow, the oncologist documents that the patient did not receive anti-EGFR monoclonal antibody therapy due to one of several reasons (e.g., RAS mutation positive, clinical contraindication, prior severe hypersensitivity, treatment plan change, or patient refusal). Typical sites of service include outpatient oncology clinic evaluation, hospital outpatient infusion center, or ambulatory surgery center when treatment decisions are made or documented. Typical patient scenario: a 62-year-old patient with metastatic colorectal adenocarcinoma undergoes molecular testing showing KRAS mutation; the oncology team documents that anti-EGFR monoclonal antibody therapy was not administered and documents the rationale in the medical record for treatment planning and billing purposes.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when additional work beyond the usual is documented for the visit that resulted in decision not to administer anti-EGFR therapy (rare for this code; use per payer rules).

HCPCS G0404: 12-Lead ECG Tracing Only for Initial Preventive Exam

HCPCS-G0206-DIAGNOSTIC-MAMMOGRAPHY-UNILATERAL-CAD

HCPCS G0206: Diagnostic Mammography, Unilateral with CAD

HCPCS-G9548-IMAGING-FINAL-REPORT-NO-FOLLOW-UP-RECOMMENDED

HCPCS G9548: Imaging Final Report — No Follow-Up Recommended

HCPCS-G0558-ADVANCED-PRIMARY-CARE-MANAGEMENT

HCPCS G0558: Advanced Primary Care Management for Complex Chronic Patients

HCPCS-G0417-PROSTATE-NEEDLE-BIOPSY-PATHOLOGY-21-40-SPECIMENS

HCPCS G0417: Prostate Needle Biopsy Pathology, 21-40 Specimens

HCPCS-G9304-PROSTHETIC-IMPLANT-SPECIFICATIONS-OPERATIVE-REPORT

HCPCS G9304: Operative Report—Prosthetic Implant Specifications

HCPCS-G8602-IV-THROMBOLYTIC-THERAPY-DELAYED-AFTER-STROKE

HCPCS G8602: IV Thrombolytic Not Initiated Within 4.5 Hours of Last Known Well

HCPCS-G9131-INVASIVE-BREAST-CANCER-DISEASE-STATUS-STAGING

HCPCS G9131: Invasive Female Breast Cancer Disease Status, Staging

HCPCS-G9979-REMOTE-IN-HOME-NEW-PATIENT-EVALUATION-VIDEO-EM

HCPCS G9979: Remote In-Home New Patient Evaluation via Video E/M

HCPCS-G9396-PHQ9-REMISSION-ASSESSMENT-12-MONTHS-NOT-ASSESSED

HCPCS G9396: PHQ-9 >9, No 12-Month Remission Assessment

Showing 1–10 of 1996

23

Taxonomy Code	Specialty	Notes
207RG0300X	Medical Oncology	Primary specialty managing systemic anti-EGFR therapy decisions and documentation.
207Q00000X	Hematology/Oncology	Combined specialty frequently involved in systemic therapy planning and infusion oversight.
363L00000X	Oncology Nursing	Nurses in infusion centers document administration decisions and manage infusions.
261QU0200X	Physician Assistant	Mid-level providers who may document treatment decisions in oncology clinics.
363A00000X	Registered Nurse	Direct care providers in infusion suites who document administration or non-administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Common primary diagnosis for which anti-EGFR therapy is considered; RAS mutation status may contraindicate therapy.
`C20`	Malignant neoplasm of rectum	Rectal cancers with metastatic disease may be evaluated for anti-EGFR therapy; molecular results guide use.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Metastatic site frequently seen in colorectal cancer influencing systemic therapy decisions.
`C79.51`	Secondary malignant neoplasm of bone	Common metastasis site that may be present when systemic therapy decisions are made.
`Z51.11`	Encounter for antineoplastic chemotherapy	Used for visits related to chemotherapy planning or administration even when a specific agent is withheld.
`Z92.21`	Personal history of antineoplastic chemotherapy	Relevant when prior adverse reactions or hypersensitivity to monoclonal antibodies influence the decision not to give anti-EGFR therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Commonly billed when anti-EGFR monoclonal antibody infusion is administered; if therapy is not given, this code would not be billed.
`96415`	Chemotherapy administration, each additional hour	Billed for extended infusion time when monoclonal antibody administration proceeds beyond the initial hour.
`96417`	Chemotherapy administration, each additional sequential infusion of a new drug via same IV access	Used when multiple agents are infused in the same encounter alongside an anti-EGFR agent; not used if anti-EGFR was not administered.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	May be used for non-chemotherapy infusions or hydration given in the same visit when anti-EGFR therapy was withheld.
`36415`	Collection of venous blood by venipuncture	Commonly performed for labs (e.g., molecular testing, baseline labs) that inform the decision not to administer anti-EGFR therapy.

OpenPayer